Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.83
-0.3050-14.32%
Volume:15.37M
Turnover:28.01M
Market Cap:68.30M
PE:-1.24
High:2.11
Open:2.08
Low:1.73
Close:2.13
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:3.64
T/O Rate:87.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.60
PE(LYR):-1.36

Loading ...

Tenax Therapeutics Shares Plunge 84.4% Premarket After Co's Heart Drug Did not Meet Main Goal in Late-Stage Study

THOMSON REUTERS
·
Aug 10

Tenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint

Reuters
·
Aug 10

Tenax Says Phase 3 LEVEL Trial of TNX-103 in PH-HFpEF Misses Primary Endpoint on 6-Minute Walk Distance

Reuters
·
Aug 10

Tenax Therapeutics' Heart Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 10

Tenax Therapeutics - Tnx-103 Generally Safe and Well Tolerated in Level Trial

THOMSON REUTERS
·
Aug 10

Tenax Therapeutics - to Request Type C Meeting with FDA for Tnx-103 Development

THOMSON REUTERS
·
Aug 10

Tenax Therapeutics - Tnx-103 Does not Meet Primary Endpoint in Phase 3 Level Trial

THOMSON REUTERS
·
Aug 10

TG Therapeutics Q2 Product Revenue Rises 70% on Briumvi Sales

Reuters
·
Aug 03

Israel's Compugen Q2 Revenue More than Doubles, Net Loss Narrows

Reuters
·
Aug 03

China's WuXi AppTec H1 Revenue Rises, Raises 2026 Guidance

Reuters
·
Aug 03

Chardan Capital Initiates a Buy Rating on Tenax Therapeutics (TENX)

TIPRANKS
·
Aug 01

Tenax Therapeutics: Buy Rating Ahead of August LEVEL Phase III Catalyst, Attractive Risk/Reward in Underserved PH-HFpEF Market

TIPRANKS
·
Aug 01

Tenax Therapeutics is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 31

Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate

Benzinga Earnings
·
Jul 31

Tenax Therapeutics Q2 Net Income USD -17.803 Million

Reuters
·
Jul 31

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jul 31

Tenax Therapeutics Q2 Operating Expenses USD 18.784 Million

THOMSON REUTERS
·
Jul 31

Tenax Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $35

THOMSON REUTERS
·
Jul 28

Tenax Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 28